Journal
GLYCOBIOLOGY
Volume 19, Issue 8, Pages 829-833Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/glycob/cwp058
Keywords
glycosyltransferase; liver; platelets; proteoglycans; serum
Categories
Funding
- NCRR NIH HHS [P20-RR018758] Funding Source: Medline
Ask authors/readers for more resources
Circulating glycosyltransferases including xylosyltransferases I (XylT1) and II (XylT2) are potential serum biomarkers for various diseases. Understanding what influences the serum activity of these enzymes as well as the sources of these enzymes is important to interpreting the significance of alterations in enzyme activity during disease. This article demonstrates that in the mouse and human the predominant XylT in serum is XylT2. Furthermore, that total XylT levels in human serum are approximately 200% higher than those in plasma due in part to XylT released by platelets during blood clotting in vitro. In addition, the data from Xylt2 knock-out mice and mice with liver neoplasia show that liver is a significant source of serum XylT2 activity. The data presented suggest that serum XylT levels may be an informative biomarker in patients who suffer from diseases affecting platelet and/or liver homeostasis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available